Difference between revisions of "Adenosquamous carcinoma of the lung"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
'''Adenosquamous carcinoma of the lung''' is a rare epithelial derived [[malignancy]] of the [[lung]] with features of both [[adenocarcinoma of the lung|adenocarcinoma]] and [[squamous cell carcinoma of the lung|squamous cell carcinoma]]. | '''Adenosquamous carcinoma of the lung''', also '''lung adenosquamous carcinoma''', is a rare epithelial derived [[malignancy]] of the [[lung]] with features of both [[adenocarcinoma of the lung|adenocarcinoma]] and [[squamous cell carcinoma of the lung|squamous cell carcinoma]]. | ||
It is grouped with the [[non-small cell lung cancer]]s. | It is grouped with the [[non-small cell lung cancer]]s. | ||
Revision as of 01:49, 9 April 2014
Adenosquamous carcinoma of the lung, also lung adenosquamous carcinoma, is a rare epithelial derived malignancy of the lung with features of both adenocarcinoma and squamous cell carcinoma.
It is grouped with the non-small cell lung cancers.
General
- Rare.
- Respond to tyrosine kinase inhibitors.[1][2]
Microscopic
Features:
- Adenocarcinoma component.
- Squamous cell carcinoma component.
See also
References
- ↑ Song, Z.; Lin, B.; Shao, L.; Zhang, Y. (Sep 2013). "Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.". J Chin Med Assoc 76 (9): 481-5. doi:10.1016/j.jcma.2013.05.007. PMID 23769878.
- ↑ Iwanaga, K.; Sueoka-Aragane, N.; Nakamura, T.; Mori, D.; Kimura, S. (2012). "The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib.". Intern Med 51 (19): 2771-4. PMID 23037472.